A B S T R A C T In the plasma clot culture system, both normal and polycythemia vera (PV) bone marrow cells respond to erythropoietin (Ep), giving rise to large numbers of colonies of erythroid cells. In PV, but not in normal individuals, the marrow produced endogenous erythroid colonies (EEC) in the absence of exogenous Ep. The number of EEC formed varied from patient to patient comprising anywhere from 6 to 29% of the total number of colonies formed in the presence of Ep. Exposure, before use in culture, of fetal calf serum and citrated bovine plasma to the gammaglobulin fraction of rabbit anti-Ep serum followed by treatment with goat anti-rabbit gamma-globulin resulted in a significant decrease in EEC formation. Addition of anti-Ep directly to the culture medium produced similar results. In addition, the production of EEC in response to added Ep was inhibited in the presence of anti-Ep. Addition of very small doses of highly purified Ep to anti-Ep-treated cultures resulted in the reappearance of a significant number of EEC. These results suggest that EEC formation in PV may be due to a population of erythroid-committed precursors that are abnormally sensitive to small concentrations of Ep which may be present in fetal calf serum and citrated plasma. Although the mechanism of formation of these cells is not known, it appears that the final steps in the formation of red cells derived from this clone of precursors is subject to the usual Ep control.
INTRODUCTION
Erythrocyte production in normal animals and man is regulated by the hormone erythropoietin (Ep)l (1) .
Alterations in the rate of production of this hormone can lead to changes in the numbers of circulating erythrocytes (2) . It is generally accepted that the increased production of erythrocytes in all cases of secondary polycythemias is associated with increased Ep formation (3) . Such an association can not be demonstrated in polycythemia vera (PV). In this regard, the decreased levels of Ep in PV (4) , and the failure to elicit a normal response to Ep by bone marrow cells of these patients in vitro (5, 6 ) have led to the suggestion that the increased production of erythrocytes in PV results from the proliferation and differentiation of hemopoietic precursor cells not under the usual Ep control (2) . Studies in vivo (7) (8) (9) and in other in vitro systems (10) (11) (12) have provided evidence for the existence also of a population of Ep-responsive erythroid precursor cells in PV. The latter cell population, however, was suggested not to contribute significantly to the overall production of erythrocytes during the active phase of the disease (2) . Recent studies, utilizing culture procedures conducive to the proliferation and differentiation of erythroid precursor cells in vitro (13) , indicated that the latter cell population may represent a greater proportion of the total erythroid precursor cell pool in PV than previously assumed (10, 12) . These studies also provided further evidence for the existence of an erythroid stem cell population in PV with altered proliferative characteristics (10) (11) (12) . Thus, whereas in the plasma clot culture system (13) bone marrow cells from hematologically normal humans exhibit erythroid activity (erythroid colonies, EC) only in the presence of relatively high concentration of Ep, PV bone marrow formed erythroid colonies (endogenous erythroid colonies, EEC) in the absence of such exogenous Ep. Addition of Ep, however, resulted in the formation of significantly greater numbers of colonies by PV bone marrow cells (10, 12) . In this report, the mechanism of EEC formation was investigated in patients with PV. The results indicate that like EC, the formation 6 who, in addition to phlebotomy, had received chemotherapy or radioactive phosphorous, and 6 patients with no prior treatment. The patients on chemotherapy or 32p had not received such therapy for a minimum of 2 yr before these studies. At the time of these studies, all PV patients had active PV (see Table I ). Bone marrow cells from five patients with a history of erythroid hyperplasia (three with erythrocytosis secondary to elevated Ep levels, and two with hemolytic anemia) were also studied. Serum and urinary Ep levels for all individuals were determined in exhypoxic polycythemic mice (14) . Female CF-1 mice were rendered polycythemic by exposure to 0.4 atm 19 h/day for a total of 216 h. Each mouse received intraperitoneal injections of either 0.5 ml of serum or 1 ml of reconstituted urine concentrate/day on days 5 and 6 posthypoxia. Radioiron (0.5 ItCi/ mouse) was given intravenously on day 6 and the percent erythrocyte-59Fe uptake was determined on day 9. 6-10 mice were used to test each sample. Urine concentrates were prepared from 24-h urine specimens (two from each patient) by dialysis against Carbowax (Union Carbide Corporation, New York) after the procedure outlined by Adamson et al. (15 Absorption against human urinary protein was achieved by incubating 20 ml of the antiserum with an amount of urinary protein separated by dialysis and ultrafiltration from 3 liters of normal urine for 1 h at 37°C followed by an additional incubation for 5 h at 40C. The mixture was centrifuged at 20,000 g for 15 min and the supernate was used in subsequent studies. In these studies, the IgG fraction of the immune serum separated by DEAE-Sephadex (Pharmacia Fine Chemicals Inc., Piscataway, N. J.) chromatography (17) was used. Similarly prepared gamma-globulin fraction from normal rabbit serum was used as control. 1 mg of the IgG from the immune serum was found to neutralize approximately 6 IU of human urinary Ep. In studies shown in Fig. 1 and Table V, 1 mg of either the normal or immune IgG was added to each cell concentration at the start of the culture.
Bone marrow cells (4 x 105 cells) from seven patients with PV were cultured in the presence or absence of 2 IU Ep as follows. Each marrow was culttured in media containing either untreated fetal calf serum (FCS) and citrated bovine plasma (CBP), FCS and CBP which were pretreated with IgG from normal rabbit serum, or FCS and CBP which were treated as follows. To 50 ml of each was added either 3 mg of normal rabbit serum IgG or IgG from immunized rabbits, incubated at 37°C for 2h with constant shaking and allowed to stand at 40C for 22 h. To each mixture was then added 6 mg of IgG separated from a commercially prepared goat anti-rabbit gamma-globulin serum (GARGG) (Antibodies Inc., Davis, Calif.), mixed thoroughly, and then allowed to stand for 2h at 40C. The mixtures were spun at 10,000 g for 20 min, the precipitate discarded, and the supemate was then passed through a Millipore filter (Millipore Corp., Bedford, Mass.) and used in cultures. The untreated FCS and CBP were also subjected to a similar procedure but without the addition of the IgG to insure uniform conditions.
In separate studies, bone marrow cells from three patients with PV were studied as follows. Each marrow (6 x Table IV depict the composite data from all donors in each category. (Fig. 2) . Addition of 2 IU Ep (75 IU/mg protein) to these cells resulted in the formation of significantly greater numbers of EC than when Ep was absent (Fig. 2) . It should be noted that the values given in Fig. 2 22 , and 24 were studied (see Table I ). § The amount represents Ep concentration/l.1 ml of culture. (14) . There is little doubt that sera from normal adult animals and man (21) and normal mammalian fetus (22) (Table IV) . Therefore, these precursor elements in PV bone marrow appear to be far more sensitive to Ep than normal erythroid precursors. Additional support for this contention is derived from the finding that after the inhibition of EEC formation by neutralization of Ep (8) and hypoxia (7) by increased red cell production. This increase occurred only in those patients in whom a rise in Ep production was detected (9) . The presence of a population of cells highly sensitive to Ep would be compatible with increased erythropoiesis in the face of low levels of circulating Ep in these patients. PV is a panmyelopathy, probably clonal in nature (19) , involving all three formed elements of the blood. Thus, any consideration of the regulation of erythropoiesis in this disorder must also include an explanation for the increased production of leukocytes and platelets, since it is unlikely that the basic defect is different for the three cell types. The results presented here do not provide evidence for or against the clonal nature of this disease. However, evidence is provided to indicate that the final steps in the fonnation of erythrocytes in PV are subject to the usual Ep control. It is conceivable that a similar mechanism could be involved in the regulation of platelet and leukocyte formation. The role of the myelostimulatory factor suggested to be present in some patients with PV (12, 23, 24) in the regulation of hematopoiesis in this disorder remains to be determined.
